Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells

BARAN Y., Ural A. U., GÜNDÜZ U.

HEMATOLOGY, vol.12, no.6, pp.497-503, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 6
  • Publication Date: 2007
  • Doi Number: 10.1080/10245330701384179
  • Journal Name: HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.497-503
  • Keywords: multidrug resistance, BCR/ABL, imatinib mesylate, chronic myeloid leukemia, Meg-01 cell line, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE, INHIBITION, APOPTOSIS, MESYLATE, THERAPY, EXPRESSION, CERAMIDE, PROTEINS, CANCER
  • Middle East Technical University Affiliated: Yes

Abstract

A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib, which has shown striking activity in the chronic phase and the accelerated phase, but less so in the blast phase of the disease. Despite high rates of hematologic and cytogenetic responses to therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of patients with CML.